Table 3. Best response to treatment.
| XELIRI plus bevacizumab (%) | |
|---|---|
| Complete response | 2 (4) |
| Partial response | 29 (63) |
| Objective response | 31 (67) |
| Progressive disease | 12 (6.5) |
| R0 resection | 6 (13) |
Abbreviation: XELIRI=capecitabine and irinotecan.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.